Cd47-car-t cells
AssigneesProMab Biotechnologies, Inc., Forevertek Biotechnology Co., Ltd
InventorsLijun Wu, Vita Golubovskaya
Life of this patent
Estimating the term…
Abstract
The present invention provides a chimeric antigen receptor (CAR) fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv has an activity against CD47, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. In one embodiment, the scFv is derived from a humanized anti-CD47 antibody. The present invention also provides T cells modified to express the CAR of the present invention.
Claims14
A chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus:
- (i) a single-chain variable fragment (scFv) comprising VH and VL, wherein scFv is against CD47 tumor antigen,
- (ii) a transmembrane domain,
- (iii) a co-stimulatory domain of CD28,
- (iv) an activating domain.
Dependencies are inferred from the claim text.